Recent Updates
Recently added Catalysts
GUTS Positive Sentiment Score: 65/100

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Key Takeaway: Fractyl Health, a clinical stage metabolic therapeutics company, is set to report its first quarter 2026 financial results and provide business updates on May 12, 2026. The event will be accessible via webcast. Additionally, CEO Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026, highlighting the company's commitment to transparency and investor relations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Fractyl Health will report financial results soon, indicating ongoing operations.
  • The company is focused on innovative treatments for obesity and type 2 diabetes.
  • Upcoming investor conference participation can enhance its visibility and engagement.

Full Press Release Details

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m. ET.
A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 9:20 a.m. PT (12:20 p.m. ET).
A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.
About Fractyl Health
Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200

Frequently Asked Questions

When will Fractyl Health report Q1 2026 financial results?

Fractyl Health will report its Q1 2026 financial results on May 12, 2026, at 4:30 p.m. ET.

Where can I watch Fractyl Health's upcoming conference call?

You can access the live webcast of the conference call at Fractyl Health's website.

Who is presenting at the BofA Securities Health Care Conference?

Harith Rajagopalan, M.D., Ph.D., will present at the BofA Securities conference.

What diseases does Fractyl Health focus on treating?

Fractyl Health specializes in treating obesity and type 2 diabetes.

What are Fractyl's main therapeutic candidates?

Fractyl's main candidates are Revita® and Rejuva®, targeting metabolic diseases.

Last updated: May 5, 2026